Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

80 results about "Xenopus" patented technology

Xenopus (/ˈzɛnəpəs/) (Gk., ξενος, xenos=strange, πους, pous=foot, commonly known as the clawed frog) is a genus of highly aquatic frogs native to sub-Saharan Africa. Twenty species are currently described within it. The two best-known species of this genus are Xenopus laevis and Xenopus tropicalis, which are commonly studied as model organisms for developmental biology, cell biology, toxicology, neuroscience and for modelling human disease and birth defects.

Carrier incapable of generating frameshift mutation after recombination as well as method and application for gene fixe-point knock-in in Xenopus laevis genome

The invention provides a carrier incapable of generating frameshift mutation after recombination as well as a method and an application for gene fixe-point knock-in in a Xenopus laevis genome. The method comprises steps as follows: (1), guide RNA (ribonucleic acid), Cas9 nuclease and a donor carrier with a pancreas ela-fluorescent screening label and a Cas9 target fragment are contained in a fertilized egg of Xenopus laevis; (2) under the joint action of guide RNA and Cas9 nuclease, a target gene in the Xenopus laevis genome and the double-chain Cas9 target fragment on the donor carrier are shorn; (3), gene fixed-point knock-in of the Xenopus laevis genome is realized through a DNA (deoxyribonucleic acid) recovery function of Xenopus laevis cells; (4), G0-generation embryos are screened through the pancreas ela-fluorescent screening label, and F1 is subjected to southern blot identification. The carrier incapable of generating frameshift mutation after recombination as well as the method and the application for gene fixe-point knock-in in the Xenopus laevis genome lay a foundation for research of genetics and human diseases with Xenopus laevis as a model animal.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof

The invention relates to the technical field of medical pharmaceutical engineering, relates to a pharmaceutical composition containing an NO donor and a preparation method thereof, in particular to a pharmaceutical composition containing beta-galactosylation azo ene glycol and a preparation method thereof. The pharmaceutical composition containing beta-galactosylation azo ene glycol provided by the invention comprises NO donor medicine containing beta-galactosylation azo ene glycol, sperm of xenopus laevis, montmorillonite and moisture-proofing agent; and the preparation method of the pharmaceutical composition comprises the following steps of: dissolving sperm of xenopus laevis in alcoholic solution, adding montmorllonite, fully stirring, filtering the montmorillonite, and drying; dissolving the NO donor medicine containing beta-galactosylation azo ene glycol in alcohol, then adding the montmorllonite, fully stirring, filtering the montmorillonite, volatilizing the alcohol and then adding the moisture-proofing agent, and mixing evenly, thus the pharmaceutical composition containing beta-galactosylation azo ene glycol is obtained. The pharmaceutical composition containing beta-galactosylation azo ene glycol provided by the invention is waterproof and antiacid, release time of the NO donor can be prolonged, and stable and controllable aims are achieved.
Owner:BEIJING UNIV OF CHEM TECH

Apparatus and method for electrophysiological testing

A method and apparatus for running a plurality of tests concurrently to obtain data relating to the electrophysiological properties of receptors and channels in biological membranes of test subjects, such as, for example, Xenopus oocytes. The invention further provides software for controlling, acquiring, and recording data relating to electrophysiological properties of receptors and channels in biological membranes of test subjects, such as, for example, oocytes. This invention increases the throughput rate for experiments and assays employing receptors and ion channels expressed in biological membranes of test subjects, such as, for example, oocytes. In the case of an oocyte, these receptors and channels may be natively expressed (endogenous), may be placed into the oocyte (exogenous), or may be expressed from other RNA or DNA previously placed into the oocyte (exogenous).
The invention provides a means for a sole researcher to operate a plurality of electrophysiological test stations in the time and space conventionally required by a single electrophysiological test station. The invention automates these stations and provides a means for a sole individual to perform large sets of experiments that would be physically and mentally exhausting in the absence of this invention. In addition, this invention provides efficient database and data analysis software integrated with the data acquisition software, thereby increasing the user's data-handling productivity to keep pace with the augmented data generation capacity.
Owner:ABBVIE INC

Production application of mono-subunit RNA polymerase KP34RP in long-chain mRNA synthesis

The invention discloses a production application of mono-subunit RNA polymerase KP34RP in long-chain mRNA synthesis. The mono-subunit RNA polymerase is bacteriophago-like particle mono-subunit RNA polymerase (a formula is as shown in the description). The KP34RP is used for preparing long-chain cap-cas9mRNA which is as show in a sequence list SEQ ID NO.4, IRES-cas9mRNA which is as show in a sequence list SEQ ID NO.5, and IRES-sox7mRNA which is as show in a sequence list SEQ ID NO.6, wherein cas9 is extensively applied to gene editing, and sox7 plays an important role in embryonic development.While three types of mRNA transcription template plasmids are constructed, at the gene sequence 5'-terminal and 3'-terminal, sequence elements of a nucleoplasmin positioning signal sequence NLS derived from xenopus laevis which is as shown in a sequence list SEQ ID NO.1, an internal ribosome entry site sequence IRES from hepatitis C virus which is as shown in a sequence list SEQ ID NO.2 and poly(A)+BspQI which is as shown in a sequence list SEQ ID NO.3 are added. It is guaranteed that the in-vitro synthesized mRNA can be efficiently translated to a function protein with activity in a cell. Theproduction application is uniform in product, high in purity, reaches a milligram level in average, and is capable of completely meeting market requirements to mRNA research and application.
Owner:RNASYN BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products